^
Association details:
Biomarker:Chr amplification(11)(q13)
Cancer:Hepatocellular Cancer
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

The association of chromosome 11q13 amplification with the hyperprogressive disease in unresectable hepatocellular carcinoma patients underwent the immunotherapy.

Published date:
05/26/2022
Excerpt:
Among them, 30 patients had unresectable advanced or recurrent HCC and received anti-tumoral therapy, including 18 cases (Group 1) receiving programmed cell death-1 (PD-1) monoclonal antibody immunotherapy (with or without tyrosine kinase inhibitors, TKIs) and 12 cases (Group 2) receiving local regional therapy (with or without TKIs)....Compared to non-11q13 Amp patients, patients with 11q13 Amp had worse PFS (log-rank P= 0.001) in Group 1.
DOI:
10.1200/JCO.2022.40.16_suppl.e16156